Can homocysteine stay elevated despite normal B12, folate, and MMA?

Elevated homocysteine (hyperhomocysteinemia) is a recognized clinical marker that can persist even when standard blood panels show normal serum folate, vitamin B12, and methylmalonic acid (MMA) levels. This clinical paradox occurs when intracellular utilization, parallel clearance pathways, or systemic metabolic signals are disrupted.

Intracellular transport and recycling barriers

• Cellular B12 Transport: Transcobalamin II (TCN2) delivers B12 into cells. Genetic variants such as rs1801198 decrease TCN2 expression, reducing active holotranscobalamin (holo-TC) levels in the blood. This limits intracellular cobalamin availability, impairing methionine synthase (MTR) capacity and elevating homocysteine.
• B12 Recycling: Methionine synthase reductase (MTRR) regenerates active methylcobalamin to sustain MTR activity. Impaired MTRR function reduces remethylation capacity, causing homocysteine accumulation while leaving mitochondrial B12 utilization intact, which keeps MMA levels within the normal reference range.

Parallel pathways and systemic cofactors

• Zinc-Dependent BHMT: Betaine-homocysteine S-methyltransferase (BHMT) is a zinc-dependent metalloenzyme that provides a folate- and B12-independent parallel pathway for clearing homocysteine. Zinc deficiency directly compromises BHMT-mediated clearance, leading to elevated homocysteine.
• Magnesium and ATP: Methionine adenosyltransferase (MAT) requires both magnesium and ATP to synthesize S-adenosylmethionine (SAMe). Low ATP or magnesium limits SAMe synthesis, reducing the downstream activation of cystathionine beta-synthase (CBS) and impairing transsulfuration.
• Thyroid Signaling: Low thyroid signaling (hypothyroidism) is a clinically established cause of isolated hyperhomocysteinemia and serves as a key systemic regulator to assess when elevated homocysteine presents alongside normal MMA.

Bottom line

• Bottom line: Persistent hyperhomocysteinemia despite normal serum B12, folate, and MMA can be driven by the convergence of impaired TCN2 cellular transport, MTRR recycling defects, compromised zinc-dependent BHMT clearance, magnesium- or ATP-limited SAMe synthesis, and subclinical hypothyroidism.